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Adynamic bone disease (ABD) is increasingly recognized,
especially in dialysis patients treated with oral calcium
carbonate, vitamin D supplements, or supraphysiological
dialysate calcium. We undertook this study to assess the
effect of lowering dialysate calcium on episodes of
hypercalcemia, serum parathyroid hormone (PTH) levels
as well as bone turnover. Fifty-one patients treated with
peritoneal dialysis and biopsy-proven ABD were randomized
to treatment with control calcium, 1.62 mM, or low calcium,
1.0 mM, dialysate calcium over a 16-month period. In the low
dialysate calcium group, 14 patients completed the study.
This group experienced a decrease in serum total and ionized
calcium levels, and an 89% reduction in episodes of
hypercalcemia, resulting in a 300% increase in serum PTH
values, from 6.071.6 to 24.973.6 pM (Po0.0001). Bone
formation rates, all initially suppressed, at 18.175.6 lm2/
mm2/day rose to 159759.4 lm2/mm2/day (Po0.05), into the
normal range (4108 lm2/mm2/day). In the control group,
nine patients completed the study. Their PTH levels did not
increase significantly, from 7.371.6 to 9.471.5 pM and bone
formation rates did not change significantly either, from
13.377.1 to 40.9711.9 lm2/mm2/day. Lowering of
peritoneal dialysate calcium reduced serum calcium levels
and hypercalcemic episodes, which resulted in increased
PTH levels and normalization of bone turnover in patients
with ABD.
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Renal osteodystrophy, one of the major complications
of end-stage renal disease (ESRD), although recognized
decades ago and studied extensively since then, continues
to be a challenging problem for nephrologists. In the
1970s and early 1980s, management of hyperphosphatemia,
the hyperparathyroid state, and bone aluminum deposition
was the major concern.1 Over the past 15 years, the spectrum
of renal osteodystrophy has changed, and adynamic
bone disease (ABD) has been increasingly recognized. ABD
is characterized by reduced synthesis of bone matrix
owing to decreased osteoblastic and osteoclastic activity.2 In
association with reduced bone formation rates (BFR), there is
a lack of osteoid accumulation differentiating this abnorm-
ality from osteomalacia. According to the Toronto Renal
Osteodystrophy Study, in the 1990s the most prevalent form
of bone disease was the non-aluminum-related ABD,
occurring in 34% of 256 ESRD patients who underwent
bone biopsy.2–4 In a retrospective analysis of 1429 iliac crest
biopsies performed in Italy between 1985 and 1994, 15.3%
showed non-aluminum-related adynamic bone histology. Its
frequency was fairly constant during the observational
period, whereas the prevalence of aluminum bone disease
gradually decreased, from 36 to 4%.5 In another European
study, 42% of 81 ESRD patients had biopsy-proven ABD,
with a greater frequency noted in peritoneal than in
hemodialysis (HD)-treated patients.6 A similar result was
shown by Sa´nchez et al.,7 who found a 63.2% frequency of
low turnover bone disease in 57 patients treated with
peritoneal dialysis. Interestingly, 32% of patients with
advanced renal failure, before initiation of renal replacement
therapy, had ABD, in spite of avoiding any vitamin D
therapy.8
One of the unresolved issues is whether ABD is
a disease or just an asymptomatic condition. Theoretically,
low BFR predisposes patients to the risk of poor healing
of microfractures and increased fracture incidence.9,10
Also, as the calcium (Ca)-buffering effect of bone is
diminished, patients on Ca-containing phosphate binders
and high dialysate Ca may have frequent episodes of
hypercalcemia.1 In addition, these episodes of hypercalcemia
may result in Ca deposition in the vasculature and
myocardium, shortening life expectancy in the ESRD
population.11
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The serum Ca level is one of the major determinants of
parathyroid hormone (PTH) secretion. In continuous
ambulatory peritoneal dialysis (CAPD) patients, the con-
tinuous positive Ca balance resulting from the elevated
dialysate Ca may result in suppressed PTH levels. Conse-
quently, the present study was undertaken to investigate the
role of suppressed PTH levels in the development of low
turnover bone disease. The aim was to assess whether
lowering of dialysate Ca is able to enhance PTH secretion,
increase BFR, and improve bone histology in patients treated
with peritoneal dialysis and biopsy-proven ABD.
RESULTS
The patients’ biochemical results are summarized in Table 1.
By lowering the peritoneal dialysis fluid Ca content, in the
low Ca group, serum total Ca (tCa) decreased from
2.4370.06 to 2.1370.03 mM (Po0.001), and serum-ionized
Ca (iCa) dropped from 1.2570.02 to 1.0970.02 mM
(Po0.0001). There was no significant change in tCa (from
2.1970.08 to 2.1870.03 mM) and iCa levels (from
1.1870.01 to 1.1570.02 mM) in the control Ca group. The
serum PTH level rose significantly, from 6.071.6 to
24.973.6 pM, when administering low Ca peritoneal dialysis
fluid (Po0.0001), but it did not show significant change,
7.371.6 pM at baseline and 9.471.5 pM after 16.372.1
months, in the patients treated with the control dialysate
Ca (Figure 1). None of the groups demonstrated significant
differences in the serum phosphate, alkaline phosphatase, or
magnesium levels at either baseline or at the end of the study.
After an average of 16.372.1 months the bone biopsies
were repeated. In the low Ca group, the BFR increased
significantly, from 18.175.6 to 159759.4 mm2/mm2/day,
reaching the normal BFR (4108 mm2/mm2/day). In compar-
ison, no significant improvement was found in the controls,
BFR changing from 13.377.1 to 40.9711.9 mm2/mm2/day
(Figure 2). In the low Ca group, five of the 14 patients’ bone
histology altered, two to osteitis fibrosa, three to mild lesion
with nine remaining adynamic. Among the nine control
patients, bone histology changed to mild lesion in one
patient, whereas the other eight remained adynamic. Figure 3
shows the association between the individual BFR changes
(expressed as values at the end of the study minus values at
baseline) plotted against the individual PTH (expressed as
values at the end of the follow-up period minus values at
baseline).
We also determined the osteoid area, marrow fibrosis,
trabecular bone, fibrotic area, osteoid surface, eroded surface,
and percentage of stainable aluminum on the bone surface in
all biopsy specimens. None of the mean values of these
parameters showed significant differences, comparing the low
Ca or control Ca groups at any time point. Surface aluminum
in the low Ca group: 14.874.5% at baseline and 18.974.5%
at follow-up, and in the control Ca group: 14.975.4 and
20.2175.7%, did not differ significantly.
Bone mineral density was measured at the time of the first
and second biopsies. It consisted of bone mineral index and
bone mineral density at the hip, assessing the whole body,
femoral neck and trochanter areas, and lumbar spine
(L1–L4). None of these values changed significantly in either
comparison of the two groups, or within the groups at
baseline and at follow-up (Table 2). Analysis of data did not
show any impact of PTH changes on bone density.
The patients tolerated the administration of low Ca
dialysate well. Hypercalcemia, defined as serum-ionized Ca
41.35 mM, decreased in the low Ca group, from 1.670.6
down to 0.1770.09 episodes/patient-year, which was
highly significant (Po0.0005). It occurred in the control
Ca group as many as 0.6970.5 episodes/patient-year
initially, and showed a nonsignificant change to 0.5370.22
Table 1 | Biochemical results
Control Ca Low Ca
Before After P-value Before After P-value
tCa (mM) 2.1970.08 2.1870.03 NS 2.4370.06 2.1370.03 Po0.001
iCa (mM) 1.1870.01 1.1570.02 NS 1.2570.02 1.0970.02 Po0.0001
PO4 (mM) 1.7070.12 1.7270.13 NS 1.8970.13 1.9270.14 NS
Mg (mM) 1.2470.06 1.2270.03 NS 1.2170.05 1.2070.05 NS
ALP (U/l) 87.3711.4 76.578.9 NS 79.076.9 84.975.9 NS
PTH (pM) 7.371.6 9.471.5 NS 6.071.6 24.973.6 Po0.0001
Ca, calcium; tCa, total serum calcium; iCa, serum ionized calcium; PO4, serum phosphate; ALP, serum alkaline phosphatase (normal 30–110 U/l); Mg, serum magnesium;
PTH, serum parathyroid hormone (normal 1–6 pM); NS, nonsignificant.
20.6
16.7
11.1
9.47.3
8.1 7.4
10.4
7.4 8.08.0 8.1
6.9 4.8
18.3
12.1
17.5
12.5
14.2
24.9
18.8
6.0
0
5
10
15
20
25
30
0 6 12 18 24 30 36 42 48 54 60
Weeks
PT
H
 (p
M
)
Control calcium Low calcium
Figure 1 | Serum PTH levels as measured every 6 weeks during
the study period in the two treatment groups. PTH rose
significantly in the low Ca group (Po0.0001), but did not change
significantly in the control group.
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episodes/patient-year during the study. The number of
hypocalcemic episodes was small: three patients experienced
one episode each of serum-ionized Ca levels o1.0 mM. The
episodes of hypocalcemia were detected biochemically, with
the patients remaining asymptomatic during these episodes.
Hypocalcemia did not occur in the control group. According
to the study design, vitamin D was not given to any of the
patients during the study period.
DISCUSSION
It has been noted that bone pain and proximal myopathy
develop frequently in patients with aluminum-associated
bone disease. However, these complications do not char-
acterize non-aluminum-related ABD. Whether ABD is a
benign, asymptomatic condition of ESRD has been a matter
of debate since its first description. Nevertheless, a few
articles have commented on increased morbidity and
mortality associated with this condition. The two major
concerns are the frequent episodes of hypercalcemia with
possible soft tissue calcification, and increased risk for
fractures due to the impaired remodelling process.10,11 In
order to avoid these complications, the most recent Dialysis
Outcome Quality Initiative (DOQI) guidelines suggest that
in cases of ABD, PTH should be allowed to rise, aiming for
increased bone turnover rates.12
The most likely mechanism for the occurrence of ABD is
the relative hypoparathyroidism seen in these patients. As the
serum-ionized Ca level is one of the most powerful factors
affecting PTH secretion, a continuously positive Ca balance
associated with oral Ca carbonate (CaCO3) treatment,
vitamin D administration, and supraphysiological dialysate
Ca may lead to oversuppression of parathyroid gland
activity.13,14 In addition, in diabetic patients, who nowadays
represent almost 50% of the ESRD patient population, both
hyperglycemia and insulin deficiency inhibit PTH secretion,
and the advanced glycosylated end-products modified bone
matrix proteins may alter the responsiveness of osteoblasts to
the regulatory hormones and cytokines.15 Other factors have
also been associated with ABD, including parathyroidectomy,
advanced age, short dialysis history, males in the CAPD
population, malnutrition, and hypermagnesemia.5,7,9,16–20
In patients treated with CAPD, Ca mass transfer depends
on the dialysate Ca concentration, the amount of ultrafiltrate
and the patient’s actual serum-ionized Ca level. In the Ca
mass balance studies of Bender et al.,21 use of 1.75 mM
dialysate Ca resulted in a positive Ca balance in the patients,
but use of 1.25 mM Ca dialysate produced net Ca removal,
and this was proportional to the amount of ultrafiltration.
Armstrong et al.22 showed that administration of 1.25 mM
dialysate Ca resulted in decreased serum-ionized Ca levels
and increased PTH values in a 3-month period when
aluminum, but not Ca-containing, phosphate binders were
given. Nevertheless, during the second phase of that study,
Table 2 | Bone mineral density and Z-scores
Control Ca Low Ca
Before After P-value Before After P-value
Whole-body BMD (g/cm2) 1.0570.07 1.0770.05 NS 1.1170.03 1.0970.04 NS
L1–L4 BMD (g/cm2) 1.0670.07 1.0770.07 NS 0.9970.03 0.9970.03 NS
Z-score (%) 110.976.2 108.976.1 NS 99.572.8 98.973.5 NS
Femoral neck BMD (g/cm2) 0.7770.05 0.7570.05 NS 0.7570.04 0.7270.04 NS
Z-score (%) 98.175.9 94.974.2 NS 93.674.4 90.474.6 NS
Trochanter BMD (g/cm2) 0.6270.05 0.6170.06 NS 0.6570.04 0.6470.04 NS
Z-score (%) 91.476.4 89.476.6 NS 92.074.6 90.174.6 NS
BMD, bone mineral density; Z-score, number of s.d. from the age-matched average value; NS, nonsignificant.
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Figure 2 | BFR increased significantly in the low Ca group,
reaching the normal BFR, but no significant improvement was
found in the control Ca group.
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Figure 3 | Association between the individual BFR changes
(expressed as values at the end of the study minus values at
baseline) plotted against the individual serum PTH changes
(expressed as values at the end of the follow-up period minus
values at baseline).
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when Ca salts were used as phosphate binders, the ionized Ca
and PTH values returned to baseline, demonstrating that tCa
balance could be restored when the patients consumed oral
Ca medications.22 Similarly, Chagnac et al.23 found that in
spite of peritoneal Ca removal with 1.0 and 1.25 mM dialysate
Ca, the daily Ca balance was still positive owing to intestinal
absorption of the mineral in patients on CaCO3 and
alfacalcidiol treatment.
During healthy bone remodelling, an actual Ca load is
immediately buffered by bone, and hypercalcemia does not
develop. Ca kinetic studies have shown that patients with
ABD have a decreased capacity for buffering of Ca by bone
and therefore may be unable to handle an extra Ca load.24
Our previous studies have shown that hypercalcemia
(tCa42.7 mM) occurred most frequently in patients with
low turnover bone disease.13
Repeated hypercalcemic episodes and elevated Ca–pho-
sphate products enhance metastatic calcifications in soft
tissues, most importantly in the vascular system, myo-
cardium, and cardiac valves.25–27 In the study of Goodman
et al.,28 severe coronary calcifications could be detected even
in young HD patients. London et al.11 found frequent,
rapidly progressive aortic valve calcification, associated with
very poor prognosis, in ESRD patients. Although long-term
survival studies of CAPD patients with ABD are not available
yet, it theoretically seems reasonable to assume that
iatrogenic hypercalcemia may play an important role in the
cardiovascular morbidity of this population.29,30
With an impaired remodelling process, patients with ABD
are prone to poor repair of microfractures,18 and suffer more
frequent episodes of fractures. Coco and Rush31 reviewed the
hip fracture incidence and found 56 episodes in 1272 ESRD
patients over a 10-year period. This frequency was 17.4 times
higher than that seen in the general population, occurring at
a significantly younger age, resulting in a 64% mortality rate
in the affected patients. More interestingly, patients with
PTH levels less than 7.2 pM had the highest risk for hip
fractures, and even PTH levels less than 21.4 pM predicted this
complication, whereas higher values were unrelated. The
investigators also found that survival of the entire dialysis
population was significantly decreased in the subgroup of
patients with the lower PTH values.
Vertebral fractures also occur more frequently in dialysis
patients than in a healthy, age-matched population. In the
study of Atsumi et al.,32 20.9% of 187 male HD patients had
one or more vertebral compression fractures. Surprisingly,
the subgroup with the lowest tertile of serum PTH values had
the highest risk, and the subgroup with the highest tertile had
intermediate risk for this complication, suggesting that ABD,
as compared to hyperparathyroid bone disease, has a greater
predisposition for vertebral fractures.32
The benefits of low dialysate Ca include prevention of
hypercalcemia, allowing for increased use of both Ca salts
and vitamin D products. Nevertheless, long-term treatment
of unselected CAPD patients with low dialysate Ca may
result in uncontrolled PTH secretion and development of
hyperparathyroidism. Weinreich et al.33 compared the effect
of 1.0 and 1.75 mM dialysate Ca on PTH secretion in a 2-year
period in normocalcemic patients, with PTH levels of 14 and
6.4 pM, respectively. He found that in the low Ca group, 23%
of the patients developed severe secondary hyperparathyr-
oidism despite maintaining normal serum Ca levels; in
comparison, hyperparathyroidism occurred in only 10% of
the patients on 1.75 mM dialysate Ca.33 Buijsen et al.34 and
Duncan et al.35 established that in normo- and hypercalcemic
patients with pre-existing secondary hyperparathyroidism,
long-term low dialysate Ca led to a further increase in PTH
secretion, and that the higher the PTH level at baseline, the
higher the risk for the development of hyperparathyroid-
ism.34,35 The morbidity resulting from elevated serum
PTH levels is as serious as those resulting from suppressed
PTH levels.
Ca homeostasis, and therefore our therapeutic approach,
will likely be changed substantially with the increasing
administration of Ca- and metal-free phosphate binders. It
can be expected that, beside phosphate-binding properties,
the effects of these agents, for example, sevelamer hydro-
chloride, lanthanum, or polynuclear iron preparations, will
result in a more neutral Ca balance, reduced incidence of
hypercalcemic episodes and hypercalcemia-induced PTH
suppression. Indeed, Braun et al.,36 who compared the effects
of Ca-free phosphate binders and CaCO3 in a 1-year study in
hemodialysed patients, found lower serum Ca, less episodes
of hypercalcemia, and higher PTH levels in the sevelamer-
treated group despite more frequent vitamin D supplementa-
tion. Whereas PTH level decreased by 38% in the CaCO3
group, it increased by 22% in the sevelamer-treated patients.
The bone turnover also increased in the sevelamer group. The
administration of Ca-free phosphate binders also proved to
be beneficial in avoiding aortic and coronary calcifications.
Based on these findings, the preference is for non-Ca binders.
Nevertheless, many patients continue on Ca-based binders
owing to cost and tolerance issues.
In the present study, we investigated whether lowering of
peritoneal dialysate Ca concentration for an extended period
of time was able to enhance PTH secretion, and consequently
BFR, in patients with biopsy-proven ABD. The study was
designed as long as 16 months to allow sufficient time for
changes in BFR to occur, and also to assess how well the new
formulation was tolerated, that is, whether it can be
administered as maintenance therapy for CAPD patients on
a long-term basis.
Administration of 1.0 mM dialysate Ca for 16.372.1
months resulted in significantly decreased serum tCa and
iCa levels, a simultaneous 300% increase in the PTH values
and normalization of the BFR. Although we did not measure
Ca absorption from the gut, we might assume, based on the
above mentioned studies, that our patients developed a very
mildly positive or zero Ca balance when assessing the
combined effects of low Ca dialysate, Ca removal by
ultrafiltration, and intestinal Ca absorption from orally
administered CaCO3. As the bone density measurements
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did not show decreasing bone mineral content over the
16-month period, we believe that the use of low Ca dialysate
was able to stimulate PTH release without causing substantial
Ca loss from bone. Most significantly, the elevated para-
thyroid activity was able to normalize bone turnover in the
study patients, whereas no significant change could be
observed in the control group. The patients tolerated the
low dialysate Ca well, with hypocalcemia occurring infre-
quently. The number of hypercalcemic episodes decreased
significantly, which allowed us to administer sufficient
amounts of CaCO3, for phosphate control, and lowered the
risk of metastatic calcification in the patients.
Patients on low Ca dialysate improved BFR significantly,
the average BFR reaching the normal range by the time of the
second biopsy. Nevertheless, there were differences in the
increase of the individual patients’ serum PTH and BFR. On
the other hand, neither PTH nor BFR increased significantly
in the control Ca group. As the serum phosphorous levels did
not show a significant difference between the biopsies or
between the groups, we assume that changes in BRF occurred
owing to low Ca dialysate inducing gradual, continuous
increases in PTH levels. According to the data, we believe that
the predictor of BFR is the rise in serum PTH levels, rather
than the baseline PTH or phosphate levels.
Although BFR improved significantly in the low Ca group,
some of the patients’ BFR did not achieve a high enough level
to be classed as a different bone histology. It is possible that
the relatively high doses of CaCO3 were still able to maintain
a positive Ca balance in these individuals. With the new, Ca-
free phosphate binders, lower Ca intake could likely stimulate
BFR further. In our opinion, the value of our study is to
provide histological evidence that bone metabolism is
sensitive to exogenous Ca exposure, and can substantially
be altered by modifying Ca balance.
Although Ca-free phosphate binders will have a substan-
tially different effect on Ca and bone metabolism, most of the
patients on renal replacement therapy are still prescribed
CaCO3 as the phosphate binder, owing to the high cost of the
newer medications.
Although the ‘gold standard’ in assessing the patients’
bone disease is bone biopsy, measurements of PTH levels are
more widely used to guide therapeutic decisions given the
lack of widespread use of biopsies. Wang et al.37 found a close
correlation (r¼ 0.71) between intact PTH levels and BFR in
175 dialysis patients without aluminum toxicity. Based on
their results, PTH levels can be used as an alternative to a
bone biopsy in guiding clinical practice.
According to the recently published paper by Block
et al.,38 disorders of mineral metabolism play an important
role in the morbidity and mortality of patients with ESRD.
The authors pointed out that hyperphosphatemia especially,
but also moderate to severe hyperparathyroidism and
hypercalcemia, are associated with not only bone disease,
but cardiovascular disease as well. The present study was not
designed to examine cardiovascular morbidity, but provided
evidence that therapy of mineral abnormalities in dialysis
patient can be ameliorated in different ways. Our medical
decision in the future, in an individual patient, should be
based not only on the serum levels of Ca, phosphorus, or
PTH but also on considerations regarding the long-term
cardiovascular effects of our interventions.
In summary, our results suggest that in CAPD patients
with ABD, sufficient decrease of the dialysate Ca leads to
increased PTH secretion, and the enhanced hormonal activity
is able to activate bone remodelling. We propose that in
CAPD patients, as in HD patients, dialysate Ca concentration
needs to be individualized. In patients with suppressed PTH
levels and biopsy-proven ADB, temporarily lowering dia-
lysate Ca may correct relative hypoparathyroidism, normal-
izing bone turnover. Nevertheless, serum Ca and PTH levels
need to be followed carefully, and the length of treatment
with low dialysate Ca needs to be evaluated so as to avoid hypo-
calcemia, worsening bone mineral content, and development
of secondary hyperparathyroidism.
MATERIALS AND METHODS
This prospective, partially randomized study was undertaken in 51
stable ESRD patients on maintenance CAPD, each of whom had
biopsy-proven ABD. The patients underwent four 2-l exchanges per
day. Before the study, all of them were using commercially available
dialysate containing 1.62 mM Ca (Dianeal, Baxter Healthcare
Corporation, One Baxter Parkway, Deerfield, IL, USA). They were
assigned into two groups: 24 patients were switched to 1 mM Ca
(‘low Ca group’) and 27 continued CAPD with peritoneal dialysis
fluid containing 1.62 mM of Ca (‘control Ca group’). The
composition of the control dialysis solution was Na 132 mM, Cl
102 mM, Ca 1.62 mM, magnesium 0.25 mM, lactate 35 mM, and
glucose 1.5, 2.5, or 4.25% according to the need of the patients. The
low, 1.0 mM Ca dialysis solution was manufactured for the purposes
of this study, with the same Na, Cl, magnesium, and lactate
composition as the standard, commercially available solution for the
control group. The Ca concentration used in this study was lower
than what is currently commercially available, that is, dialysate Ca of
1.25 mM.
The ‘partial randomization’ means that the two groups were not
exactly comparable, the serum tCa and iCa levels tended to be
higher in the low Ca group at baseline. Owing to ethical reasons,
patients with more frequent episodes of hypercalcemia were selected
for the low Ca group. For the frequently hypercalcemic patients, the
low Ca dialysate treatment was obviously less harmful, than the
standard Ca dialysate would have been.39,40 Twenty-three of the 51
participants finished the 16.372.1 month study period, 14 in the
low Ca and nine in the control Ca group, and their data are herein
presented. Their mean ages were 5773.6 and 5674.5 years, and
their weights were 64.474.5 and 65.475.5 kg, respectively. There
were nine male and five female patients in the low Ca, and four male
and five female patients in the control Ca group. Six of 14 patients
on low Ca and four of nine patients on control Ca dialysate had
diabetes mellitus.
Serum tCa and iCa, phosphate, alkaline phosphatase, and
magnesium were measured by standard laboratory techniques
monthly. Hypercalcemia, serum tCa42.7 mM, was tracked for 6
months before initiation of study. Intact PTH levels were
determined by an immunoradiomertic assay every 6 weeks. Bone
mineral density measurements were performed at baseline and at the
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end of the study period. The patients, entered after undergoing
documentation of ABD, had a second bone biopsy performed after
16.372.1 months of treatment.
Bone biopsy specimens were obtained under local anesthesia
from the anterior iliac crest using a Bordier needle. The patients
were given two courses of tetracycline separated by a 17-day drug-
free period. The biopsy was performed 4–10 days after the last dose
of tetracycline. Bone biopsies were assessed for static and dynamic
histomorphometric parameters. Separate sections were stained for
aluminum on mineralizing bone surfaces. The diagnostic criteria for
ABD were determined as BFRo108 mm2/mm2/day, osteoid area
o15%, and marrow fibrosis o0.5%. Mild bone lesion was
diagnosed when BFRX108 mm2/mm2/day, the osteoid area o15%,
and marrow fibrosis o0.5%, and osteitis fibrosa was established if
BFRX108 mm2/mm2/day, the osteoid area o15%, and marrow
fibrosis 40.5%.
During the study period, oral CaCO3 dose was adjusted to
maintain the serum phosphate level below 2 mM. For the patients in
the low Ca group the CaCO3 dose was increased from 1.8170.25 to
3.170.57 g/day (Po0.05), and in the control group from 1.8570.37
to 2.7570.47 g/day (Po0.05).
None of the patients was ingesting vitamin D. Hypercalcemic
episodes were documented, and we also evaluated the reasons for
dropouts in each case. Of the 28 patients who dropped out, 10 were
in the low Ca group and 18 were in the control Ca group. Four
patients underwent renal transplantation, eight were switched to
HD, three were transferred to another peritoneal dialysis center,
seven became too ill for the bone studies and the repeat biopsy, and
six patients died.
The study was approved by the local institutional review board
and the patients signed a consent before being initiated in the study.
Statistical analysis
Results are expressed as the mean7s.e.m. All tests were two-sided.
Comparisons between the groups were made using unpaired and
paired t-tests. Po0.05 was considered significant.
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